{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:10:21Z","timestamp":1760735421688,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejca.2021.06.036","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T12:26:51Z","timestamp":1627907211000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-6357","authenticated-orcid":false,"given":"Jian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2021.06.036_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.06.036_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2021.06.036_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.06.036_bib4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.036_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11154-016-9357-0","article-title":"Hypothyroid myopathy: a peculiar clinical presentation of thyroid failure. Review of the literature","volume":"17","author":"Sindoni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.ejca.2021.06.036_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/07435800500371706","article-title":"Serum creatine kinase levels in overt and subclinical hypothyroidism","volume":"31","author":"Hekimsoy","year":"2005","journal-title":"Endocr Res"},{"issue":"11","key":"10.1016\/j.ejca.2021.06.036_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1089\/thy.1998.8.1033","article-title":"Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism","volume":"8","author":"Rodolico","year":"1998","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ejca.2021.06.036_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2217\/imt-2017-0174","article-title":"Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer","volume":"10","author":"Badovinac","year":"2018","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.036_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:18Z","timestamp":1760733138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":9,"alternative-id":["S0959804921004123"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}